Kristen Wotsch

National Director KOL Development & Medical Affairs

[Kristen Wotsch @kmwotsch]

@realmflynnJR This is not true information.

[ReflowMedical @reflowmedical]

How do the latest 12-month DEEPER REVEAL trial data translate into clinical benefit in BTK CLTI?

In patients with long, calcified infrapopliteal lesions, treatment with the Spur® Peripheral Retrievable Stent System following predilatation demonstrated*:

• Meaningful clinical recovery
• Reduced reintervention rates
• Sustained vessel patency

Key safety and efficacy outcomes at 12 months:

• Primary patency: 78.0%
• Freedom from clinically driven TLR: 83.1%
• Complete paired wound healing: 84.3%
• Rutherford class improvement: 80.0%]

These findings highlight the potential of Retrievable Scaffold Therapy (RST) to deliver durable vessel-related and patient-centered outcomes, supporting its role in the treatment of complex BTK disease while leaving nothing behind.

How do you define relevant outcomes for your CLTI patients in daily practice?

🔗 Read the full press release:
https://t.co/axFoY2n9R6

🔗 Full U.S. Indications for Use:
https://t.co/crn1QfbYoP

*At 12 months, vessel-related outcomes in appropriately selected vessels (core lab-measured reference vessel diameter ≥2.5 mm, per study protocol and indication for use) and patient-centered outcomes were assessed.

[ReflowMedical @reflowmedical]

Spur® is a self-expanding, retrievable, temporary stent.

It is designed to support revascularization of BTK lesions during a key phase, when overcoming vessel recoil and reduced compliance is critical.

When placed and expanded, Spur provides temporary scaffolding that supports the vessel wall and keeps the vessel open to facilitate blood flow. Incorporating radially expandable spikes, Spur is designed to enable controlled lesion penetration and lesion morphology modification to change vessel compliance and reduce the vessel recoil effect.¹

Once its mechanical task is completed, Spur is fully retrieved, leaving nothing behind.

🔗Learn how the Spur Stent System works in practice: https://t.co/uze8oVn2qh

For full Indications for Use and Important Safety Information – U.S. only (FDA), visit: https://t.co/crn1Qfcwen

1. Zeller et al. Early Tibial Vessel Recoil Following Treatment With the Bare Temporary Spur Stent System: Results from the DEEPER OUS Vessel Recoil Substudy. Journal of Endovascular Therapy. 2024;0(0). doi:10.1177/15266028241280685.

[ReflowMedical @reflowmedical]

Summit Together! was the theme of our U.S. National Sales Meeting that brought the team together around what matters most: our people, our focus, and our mission of healing wounds and saving limbs.

It was great to see the energy, openness, and commitment in the room as we aligned on what's ahead. This team understands the importance of taking responsibility for the work we do and the impact it has every day.

Thank you to our U.S. Sales Team for the drive and dedication you. bring to the field, and special appreciation goes to to the "chosen ones" honored at the awards ceremony!

#sales #teamwork #reflowmedical

[ReflowMedical @reflowmedical]

Heavy medial calcification and significant soft plaque made this CLTI case challenging and typical of real-world BTK disease.

This new case report shows how the Spur® Stent System achieved IVUS-confirmed disruption of medial calcification and supported complete wound healing in a peroneal artery lesion treated by @FadiSaab17 Fadi Saab, MD, FACC, FSCAI, FASE.

A 51-year-old male (Rutherford Class 5) with Type I diabetes and a prior kidney transplant presented with minor tissue loss of the 4th digit and a 50 mm peroneal artery lesion with heavy medial calcification, soft plaque, and 76% stenosis. After predilatation, a 3.0 × 65 mm Spur Stent was used.

IVUS post-treatment demonstrated disruption of the medial calcium ring with restored vessel pulsatility and compliance.

Outcomes:
• Complete wound healing at 3 months
• Rutherford Class 0 through 12 months
• Patency at 6 and 12 months (duplex)

📄 Read the full case report below or on our website:
https://t.co/XsWbkfhaAT

#PAD #CLTI #vascular #SpurStent

[Kristen Wotsch @kmwotsch]

@thehealthb0t Protocol

[Kristen Wotsch @kmwotsch]

@FadiSaab17 @reflowmedical @AMPSymposium @CLIjournal @OEISociety @BobTahara @bretwiechmann @_backtable @keithppereira @dandu_n @EricSecemskyMD @KNagarshethMD Great work! Thank you for your support!

[Kristen Wotsch @kmwotsch]

@WHLeavitt 10

[Kristen Wotsch @kmwotsch]

@musk_news13 Game over

[Kristen Wotsch @kmwotsch]

@musk_news13 R - reverse
Manual car

[Kristen Wotsch @kmwotsch]

@WHLeavitt F

[ReflowMedical @reflowmedical]

Stay up to date by attending the Cardiovascular Research Technologies @crfheart CRT25 forum!♥️ It's 4 days of education and training, live case studies, clinical trial updates and exciting keynote speakers, March 8-11 in Washington, DC.

We'll look forward to seeing you at booth #202 - catch up with what's new at Reflow Medical. 💬

For more information, visit https://t.co/HZoHrJQdfd

#interventionalradiology #VI #PAD #endovascular #CLTI #CLIFighters #SpurRST

[ReflowMedical @reflowmedical]

👏 A huge shout-out to Andrej Schmidt, MD for his presentation on Spur RST at the ImEndo Forum last week! We're truly grateful to him and to Prof. Marianne Brodmann, MD, who highlighted Spur RST in her talk, "Unmet needs in BTK tools and technologies."

Thank you to Course Director Fabrizio Fanelli 🙌 and to all who made the conference a success! (Awesome video on the home page, too!)

To learn more about Spur RST, visit: https://t.co/LiozX3OAl4

#interventionalradiology #VI #PAD #endovascular #CLIFighters #CLTI #Imendo2025 #SpurRST

[ReflowMedical @reflowmedical]

✨ Kicking off 2025 with purpose and passion! ✨ We recently wrapped up our annual National Sales Meeting in Fort Worth, TX, January 14–17, and what an incredible event it was! 🎉

It was an honor to welcome leading physicians Gary Ansel, MD @garyansel, Mahmood Razavi, MD, Michael Siah, MD @michaelcsiah and John Phillips, MD @MidOhioVascular. They share our commitment to combating CLTI, and their insights and expertise continue to inspire our mission of driving innovation and improving patient outcomes.

The gathering at the Bowie House Hotel brought together members of our R&D, Clinical, Regulatory, Sales, and Marketing teams, all dedicated to pushing the boundaries of what’s possible in the fight against CLTI. The energy, collaboration, and forward-thinking discussions set the stage for an exciting year ahead!

A huge thank you to everyone who participated — we couldn’t do this without you! Here’s to 2025, a year of innovation, teamwork, and making a real impact. Let’s keep the momentum going! 🚀

#interventionalradiology #VI #PAD #endovascular #CLIFighters #CLTI #savemypiggies

[ReflowMedical @reflowmedical]

Many thanks for the stellar presentations at the Leipzig Interventional Course @LINCmeeting !🌟 Kudos to @JayMathewsMD for sharing first-ever 30-day primary endpoints data from the DEEPER REVEAL trial (NCT05358353), and to Michael Lichtenberg, MD, moderator for the session, “Innovative Approaches in Treating BTK CLTI: How to Cross, Access, and Treat,” with presenters Ashwani Sastry, MD, @michaelcsiah, MD and Daniel van den Heuvel, MD. 👏

Thursday’s live case transmission “Spur® RST in conjunction with a DCB” with Andrej Schmidt, MD and Axel Fischer, MD was outstanding! 🙌

Our sincere gratitude to all!

Learn more about Spur RST here: https://t.co/LiozX3OAl4

#interventionalradiology #VI #PAD #endovascular #CLIFighters #CLTI #SpurRST #LINC2025

[ReflowMedical @reflowmedical]

On Tuesday, Feb. 4, grab a coffee ☕ and meet us in the Great Hall 4 @ISETNews for a live case from University Hospital Leipzig! Constantino Pena, MD is the moderator; the case is performed by Axel Fischer, MD and Andrej Schmidt, MD.

Later, join us for "The Role of Spur® Stent and Adjunct Balloons for Tibial Lesions" with moderators Barry Katzen, MD @DrBTKatzen and Richard Neville, MD and speaker @JayMathewsMD.

See you there! For more information, visit: https://t.co/OePgwLn5xU

#interventionalradiology #VI #PAD #endovascular #CLIfighters #CLTI #ISET2025 #SpurRST

[ReflowMedical @reflowmedical]

Watch the experts in action! 🥼 Catch the live case transmission tomorrow, Thursday Jan. 30: "Spur® RST in conjunction with a DCB," with operators @andrejschmidt3, MD and Axel Fischer, MD at the Leipzig Interventional Course @LINCmeeting . Starts at 1:48 pm.

See page 42 in the LINC 2025 Live Case Guide: https://t.co/uHQpATBN8S

#interventionalradiology #VI #PAD #endovascular #CLIfighters #CLTI #LINC2025 #SpurRST

[ReflowMedical @reflowmedical]

On Wednesday, Jan. 29th 🗓️  don’t miss the first-ever presentation of the DEEPER REVEAL (NCT05358353) primary endpoint results delivered by @JayMathewsMD. Dr. Marcus Thieme shares compelling data on the impact of Spur® RST on vessel recoil from the DEEPER OUS Vessel Recoil Substudy (NCT04162418) results.

Later in the day, join the symposium “Innovative Approaches in Treating BTK CLTI: How to Cross, Access, and Treat,” moderated by Dr Michael Lichtenberg, MD. This session features leading vascular experts sharing strategies for tackling BTK disease and exploring how Spur RST can help optimize clinical outcomes.

An exciting day at the @LINCmeeting, Leipzig Interventional Course! 🚀

We look forward to seeing you at LINC 2025 for insights and innovations in vascular intervention. https://t.co/H3tMPqb7U8

#interventionalradiology #VI #PAD #endovascular #CLTI #CLIfighters #LINC2025 #SpurRST

[ReflowMedical @reflowmedical]

Vessel recoil is frequently observed in CLI patients undergoing tibial angioplasty¹ and is a predictor for lesion revascularization in advanced PAD and CLI patients². See how Spur Retrievable Scaffold Therapy (RST) reduces vessel recoil in below-the-knee (BTK) arteries in the DEEPER OUS Vessel Recoil Substudy³.

The DEEPER OUS Vessel Recoil Substudy was published by 𝗭𝗲𝗹𝗹𝗲𝗿, 𝗧, 𝗭𝗵𝗮𝗻𝗴 𝗭, 𝗣𝗮𝗿𝗶𝘀𝗲 𝗛, 𝗲𝘁 𝗮𝗹. 𝗝𝗼𝘂𝗿𝗻𝗮𝗹 𝗼𝗳 𝗘𝗻𝗱𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗧𝗵𝗲𝗿𝗮𝗽𝘆. 𝟮𝟬𝟮𝟰;𝟬(𝟬) and showed post Spur RST more than 50% less vessel recoil compared with previously reported¹ rates with balloon angioplasty. In this substudy, 38 patients from the DEEPER OUS trial (NCT04162418) were evaluated on vessel recoil, defined as lumen compromise as ≥10% at 15 minutes post Spur treatment.

To learn more, view the study flyer below.

References: 1. Baumann et al, J ENDOVASCULAR THER 2014;1:44-51; 2. Mustapha et al. AMP 017, One Month Duplex Ultrasound Evaluation of Vessel Recoil after Tibial Peripheral Vascular Intervention for Critical Limb Ischemia Predicts 1 Month TLR; 3. Zeller T et al. Journal of Endovascular Therapy. 2024;0(0). doi:10.1177/15266028241280685

#interventionalradiology #VI #PAD #CLIfighters #endovascular #CLTI #SpurRST

[ReflowMedical @reflowmedical]

We invite you to attend two engaging presentations on Reflow Medical's Spur® RST at the @ParisVascular Insights Course. 🇫🇷

Dr. Michael Lichtenberg talks about the two-year results of the DEEPER OUS (NCT03807531) clinical trial on Thursday, Dec. 12 at 12:35. 👨‍⚕️

On Friday, Dr. Daniel van den Heuvel describes the innovative solution for CLTI known as RST at 13:30 during the @CLI_Global Society @ PVI session. 🏥

Don't forget to stop by Booth 28 and say hello! 🙂

Learn more about PVI at: https://t.co/z0aOxyDoIF

For information about RST, visit: https://t.co/LiozX3OAl4

#endovascular #interventionalradiology #VI #PAD #CLIfighters #CLTI #SpurRST